Biogen (BIIB.US) stock has been halted after the FDA has approved its controversial Alzheimer drug Aducanumab using an accelerated approval pathway. It is the first Alzheimer's treatment approved in 18 years, according to CNBC. Biogen still needs to conduct a postapproval clinical trial and FDA pointed out that the approval may be withdrawn upon unfavorable results.
Biogen (BIIB.US) stock was halted for trading at $286.10 and awaits reopening. Source: xStation5
Arista Networks shares jump 6% after earnings 📈 Revenue growth hits its highest level since IPO
AMD shares jump 7% after stellar earnings 🔼 Will semiconductor stocks return to growth?
Daily Summary: Chips lift Wall Street on Election Day, oil drops amid progress in negotiations (03.11.2026)
US Open: Lower oil prices boost indices, markets await Midterms results (03.11.2026)